Augusto Villanueva serves as the Medical Director of the Liver Cancer Program at NYU Langone Health in New York. He earned his medical degree from the University of Santiago de Compostela in Spain. His previous roles include Associate Professor in the Division of Liver Diseases at Mount Sinai Hospital and Senior Lecturer and Consultant Hepatologist at the Institute of Liver Studies at King’s College Hospital in London. Dr. Villanueva is a NIH-funded physician-scientist whose work integrates clinical practice as a hepatologist with research aimed at elucidating the role of intratumor heterogeneity in cancer evolution and developing innovative minimally invasive biomarkers through liquid biopsy. He has authored over 160 publications, accumulating more than 30,000 citations and an H-index of 72. His works have been featured in prestigious journals such as New England Journal of Medicine, Nature Genetics, Nature Biotechnology, Nature Communications, Gastroenterology, Hepatology, Journal of Hepatology, Gut, Journal of Clinical Investigation, and Oncogene. Dr. Villanueva is recognized among the top 1% most highly cited researchers for the years 2023 and 2024 by Clarivate. Additionally, he has contributed to more than 15 book chapters and edited a comprehensive volume on resistance to targeted therapies in hepatocellular carcinoma (HCC). He has held editorial positions as Associate Editor for the Journal of Hepatology and Liver Cancer, and has served as the Executive Secretary of the International Liver Cancer Association.